Comparative Pharmacology
Head-to-head clinical analysis: ESOMEPRAZOLE STRONTIUM versus PROTONIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESOMEPRAZOLE STRONTIUM versus PROTONIX.
ESOMEPRAZOLE STRONTIUM vs PROTONIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor that inhibits the H+/K+ ATPase in gastric parietal cells, suppressing gastric acid secretion.
Proton pump inhibitor that inhibits the H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells, blocking the final step of gastric acid secretion.
40 mg orally once daily; for healing of erosive esophagitis, 40 mg orally once daily for 4-8 weeks; for maintenance of healing of erosive esophagitis, 20 mg orally once daily; for GERD, 20 mg orally once daily; for Helicobacter pylori eradication, 40 mg orally twice daily for 10 days in combination with antibiotics.
40 mg orally once daily; alternatively, 40 mg IV once daily for 7-10 days.
None Documented
None Documented
Terminal elimination half-life: 1.0–1.5 hours in healthy subjects; prolonged in poor CYP2C19 metabolizers (up to 3.5 hours).
Terminal elimination half-life is about 1–2 hours in healthy individuals; in CYP2C19 poor metabolizers or hepatic impairment, half-life may increase up to 3–6 hours, but clinical impact is minimal due to irreversible binding to H+/K+-ATPase.
Primarily hepatic metabolism via CYP2C19 and CYP3A4. Approximately 80% of metabolites are excreted in urine and 20% in feces via bile. Less than 1% excreted unchanged.
Approximately 80% of a dose is excreted as metabolites in urine, with the remainder (≈20%) in feces via biliary elimination.
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor